Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Arun J SanyalT D BoyerR T FrederickF WongL RossaroV ArayaH E VargasK R ReddyS C PappasP TeuberS EscalanteK JamilPublished in: Alimentary pharmacology & therapeutics (2017)
Terlipressin plus albumin resulted in a significantly higher rate of HRS reversal vs. albumin alone in patients with HRS-1. Terlipressin treatment is associated with improved renal function. (ClinicalTrials.gov identifier: OT-0401, NCT00089570; REVERSE, NCT01143246).